Frentizole, a Nontoxic Immunosuppressive Drug, and Its Analogs Display Antitumor Activity via Tubulin Inhibition
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242417474 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Sergio Ramos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Campus Miguel de Unamuno, Universidad de Salamanca, 37008 Sal…. Hauptthemen laut MEDLINE: Antimitotic Agents, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Consejería de Educación Junta de Castilla y León, European Union (EU) program "ERDF A way of making Europe".
Abstract (Originalsprache)
Antimitotic agents are one of the more successful types of anticancer drugs, but they suffer from toxicity and resistance. The application of approved drugs to new indications (i.e., drug repurposing) is a promising strategy for the development of new drugs. It relies on finding pattern similarities: drug effects to other drugs or conditions, similar toxicities, or structural similarity. Here, we recursively searched a database of approved drugs for structural similarity to several antimitotic agents binding to a specific site of tubulin, with the expectation of finding structures that could fit in it. These searches repeatedly retrieved frentizole, an approved nontoxic anti-inflammatory drug, thus indicating that it might behave as an antimitotic drug devoid of the undesired toxic effects. We also show that the usual repurposing approach to searching for targets of frentizole failed in most cases to find such a relationship. We synthesized frentizole and a series of analogs to assay them as antimitotic agents and found antiproliferative activity against HeLa tumor cells, inhibition of microtubule formation within cells, and arrest at the G2/M phases of the cell cycle, phenotypes that agree with binding to tubulin as the mechanism of action. The docking studies suggest binding at the colchicine site in different modes. These results support the repurposing of frentizole for cancer treatment, especially for glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Campus Miguel de Unamuno, Universidad de Salamanca, 37008 Salamanca, Spain.
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Facultad de Farmacia, Campus Miguel de Unamuno, Universidad de Salamanca, 37008 Salamanca, Spain.
- Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Facultad de Farmacia, Campus Miguel de Unamuno, Universidad de Salamanca, 37008 Salamanca, Spain.
ORCID-Profile: Laura Gallego-Yerga, Raquel Álvarez, Rafael Peláez
Förderung
- Ministerio de Ciencia e Innovación
- Consejería de Educación Junta de Castilla y León
- European Union (EU) program "ERDF A way of making Europe"
- MCINN/AEI/10.13039/501100011033
- Consejería de Educación de la Junta de Castilla y León
- European Union (EU)
Zitieren
APA
Ramos, S., Vicente-Blázquez, A., López-Rubio, M., Gallego-Yerga, L., Álvarez, R., & Peláez, R. (2023). Frentizole, a Nontoxic Immunosuppressive Drug, and Its Analogs Display Antitumor Activity via Tubulin Inhibition. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417474
Vancouver
Ramos S, Vicente-Blázquez A, López-Rubio M, Gallego-Yerga L, Álvarez R, Peláez R. Frentizole, a Nontoxic Immunosuppressive Drug, and Its Analogs Display Antitumor Activity via Tubulin Inhibition. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417474
BibTeX
@article{Ramos2023,
author = {Ramos, Sergio and Vicente-Blázquez, Alba and López-Rubio, Marta and Gallego-Yerga, Laura and Álvarez, Raquel and Peláez, Rafael},
title = {Frentizole, a Nontoxic Immunosuppressive Drug, and Its Analogs Display Antitumor Activity via Tubulin Inhibition},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242417474}
}
EUVIMED